Thrombophilia testing in patients taking direct oral anticoagulants. Handle with care
Key result
Direct oral anticoagulants do not significantly bias chromogenic protein C or free protein S assays, but utilizing mismatched chromogenic assays for antithrombin can lead to false deficiencies.
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
Requires careful assay selection for thrombophilia testing on DOACs; leaves optimal protocols open for prospective validation.
PICO
P
Population
Patients taking direct oral anticoagulants requiring thrombophilia testing
E
Exposure / Comparator
Direct oral anticoagulants (DOACs)
When performing thrombophilia testing in patients on DOACs, specific assay types (e.g., chromogenic vs. clot-based) must be carefully selected to prevent false-positive deficiency results.
Cite This Study
Lippi et al. (2014) conducted a letter in Patients taking direct oral anticoagulants requiring thrombophilia testing. Direct oral anticoagulants (DOACs) was evaluated. Direct oral anticoagulants do not significantly bias chromogenic protein C or free protein S assays, but utilizing mismatched chromogenic assays for antithrombin can lead to false deficiencies.